---------------------------------------------------------------
详细处方信息以本药内容附件PDF文件（201931122195217.pdf）的“原文Priscribing Information”为准
---------------------------------------------------------------
部分中文爱宁达霜处方资料（仅供参考）

【英文名称】Elidel

【适用证】

爱宁达霜1％是钙调神经磷酸酶抑制剂免疫抑制剂，适用于非免疫功能低下成人和2岁及以上儿童的轻度至中度特应性皮炎的短期和非连续慢性治疗的二线治疗 未能对其他局部处方治疗做出充分反应，或者当这些治疗方法不可取时。（1）

【用法用量】

每天两次在受影响的皮肤上涂一层薄薄的ELIDELCream，1％。（2）

如果症状和体征持续超过6周，应重新检查患者。（2）

持续长期使用ELIDELCream，应避免1％。（2）

避免使用闭合敷料。（2）

【注意事项】

ELIDELCream，1％禁用于对吡美莫司或乳膏任何成分有过敏史的个体。

不应用于免疫功能低下的成人和儿童，包括全身免疫抑制药物的患者。（5.1）

避免在恶性或恶变前的皮肤状况下进行治疗，因为这些可能会引起皮炎。（5.2）

不应用于Netherton综合症患者或可能增加全身吸收的皮肤病患者。（5.2）

【INDICATIONS AND USAGE】

ELIDELCream, 1% is a calcineurin inhibitor immunosuppressant indicated as second-line therapy for the short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised adults and children 2 years of age and older, who have failed to respond adequately to other topical prescription treatments, or when those treatments are not advisable. (1)

【DOSAGE AND ADMINISTRATION】

Apply a thin layer of ELIDELCream, 1% to the affected skin twice daily. (2)

If signs and symptoms persist beyond 6 weeks, patients should be re examined. (2)

Continuous long-term use of ELIDELCream, 1% should be avoided. (2)

Avoid use with occlusive dressings. (2)

【CONTRAINDICATIONS】

ELIDELCream, 1% is contraindicated in individuals with a history of hypersensitivity to pimecrolimus or any of the components of the cream. (4, 6.2)

【WARNINGS AND PRECAUTIONS】

Should not be used in immunocompromised adults and children, including patients on systemic immunosuppressive medications. (5.1)

Avoid treatment on malignant or pre-malignant skin conditions, as these can present as dermatitis. (5.2)

Should not be used in patients with Netherton’s Syndrome or skin diseases with a potential for increased systemic absorption. (5.2)

---------------------------------------------------------------
详细处方信息以本药内容附件PDF文件（201931122195217.pdf）的“原文Priscribing Information”为准
---------------------------------------------------------------